You are here: Industry Insights > Sofosbuvir

News List

U.S. Food and Drug Administration Approves New Formulation of Epclusa, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C firstwordpharma
June 11, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that FDA has approved an expansion of the pediatric indication of Epclusa® for the treatment of chronic hepatitis C virus (HCV) to now include children as young as 3 years of age
Sofosbuvir found to be effective against Zika virus europeanpharmaceuticalreview
April 29, 2019
In both cell cultures and mouse models, sofosbuvir a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus — and blocked transmission of the virus to mouse fetuses.
Sofosbuvir found to be effective against Zika virus europeanpharmaceuticalreview
April 29, 2019
A drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus…
Sofosbuvir can be a potential treatment for patients with Zika virus europeanpharmaceuticalreview
January 29, 2018
A drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus…